|
M variables
|
ORSCL (95%CI)
|
ORVF (95%CI)
|
ORMH (95%CI)
|
ORG (2.5–97.5pct)
|
|---|
|
1
|
exp(β)
|
4.26 (2.72–6.66)
|
4.27 (2.73–6.68)
|
4.55 (2.37–8.73)
|
4.26 (2.85–7.33)
|
|---|
| |
exp(γ)
|
1.68 (1.02–2.78)
|
1.86 (1.11–3.11)
| |
1.68 (1.03–2.96)
|
|
2
|
exp(β)
|
4.04 (2.85–5.75)
|
4.04 (2.85–5.73)
|
3.82 (2.49–5.86)
|
4.04 (2.78–6.11)
|
| |
exp(γ)
|
1.84 (1.15–2.94)
|
2.06 (1.28–3.30)
| |
1.84 (1.19–2.92)
|
|
3
|
exp(β)
|
3.62 (2.60–5.04)
|
4.11 (2.83–5.97)
|
4.17 (2.71–6.43)
|
4.10 (2.93–5.82)
|
| |
exp(γ)
|
2.12 (1.43–3.12)
|
1.93 (1.31–2.86)
| |
2.21 (1.45–3.37)
|
|
4
|
exp(β)
|
3.91 (2.86–5.34)
|
4.19 (3.03–5.79)
|
3.91 (2.66–5.75)
|
4.09 (3.00–5.67)
|
| |
exp(γ)
|
2.14 (1.48–3.11)
|
2.43 (1.66–3.54)
| |
2.20 (1.45–3.26)
|
|
5
|
exp(β)
|
4.36 (3.18–5.97)
|
4.07 (3.00–5.51)
|
4.04 (2.78–5.86)
|
4.02 (2.93–5.57)
|
| |
exp(γ)
|
1.86 (1.29–2.66)
|
2.35 (1.62–3.41)
| |
1.92 (1.28–2.86)
|
|
6
|
exp(β)
|
4.78 (3.51–6.52)
|
3.98 (2.88–5.50)
|
4.15 (2.93–5.88)
|
4.12 (3.00–5.77)
|
| |
exp(γ)
|
1.92 (1.36–2.71)
|
2.00 (1.37–2.92)
| |
1.87 (1.33–2.63)
|
|
7
|
exp(β)
|
4.48 (3.26–6.15)
|
–
|
4.42 (3.10–6.30)
|
4.04 (2.94–5.59)
|
| |
exp(γ)
|
1.89 (1.34–2.67)
|
2.03 (1.33–3.08)
| |
1.86 (1.30–2.70)
|
|
8
|
exp(β)
|
4.90 (3.57–6.74)
|
4.07 (2.50–6.63)
|
3.88 (2.79–5.42)
|
4.07 (2.93–5.68)
|
| |
exp(γ)
|
1.81 (1.29–2.53)
|
1.76 (1.17–2.64)
| |
1.79 (1.24–2.51)
|
|
9
|
exp(β)
|
5.24 (3.81–7.22)
|
4.10 (2.76–6.08)
|
4.47 (3.22–6.19)
|
4.08 (2.96–5.65)
|
| |
exp(γ)
|
1.77 (1.27–2.48)
|
2.10 (1.42–3.10)
| |
1.75 (1.23–2.48)
|
|
10
|
exp(β)
|
5.08 (3.67–7.03)
|
–
|
4.13 (2.99–5.70)
|
4.06 (2.94–5.61)
|
| |
exp(γ)
|
1.77 (1.28–2.45)
|
1.62 (1.08–2.42)
| |
1.76 (1.26–2.50)
|
|
11
|
exp(β)
|
5.33 (3.85–7.38)
|
4.07 (2.17–7.64)
|
4.15 (3.01–5.72)
|
4.07 (2.96–5.65)
|
| |
exp(γ)
|
1.78 (1.29–2.46)
|
1.86 (1.26–2.76)
| |
1.73 (1.23–2.38)
|
|
12
|
exp(β)
|
5.61 (4.06–7.75)
|
4.12 (2.69–6.32)
|
4.51 (3.29–6.18)
|
4.07 (2.95–5.62)
|
| |
exp(γ)
|
1.92 (1.39–2.66)
|
1.81 (1.24–2.64)
| |
1.86 (1.34–2.62)
|
|
13
|
exp(β)
|
5.81 (4.19–8.04)
|
4.06 (2.79–5.91)
|
4.65 (3.40–6.36)
|
4.02 (2.90–5.56)
|
| |
exp(γ)
|
1.93 (1.39–2.68)
|
1.87 (1.28–2.73)
| |
1.88 (1.34–2.61)
|
|
14
|
exp(β)
|
5.60 (4.02–7.79)
|
–
|
4.05 (2.96–5.55)
|
3.99 (2.87–5.53)
|
| |
exp(γ)
|
1.93 (1.40–2.66)
|
2.10 (1.40–3.13)
| |
1.87 (1.35–2.57)
|
|
15
|
exp(β)
|
5.83 (4.17–8.13)
|
3.94 (2.42–6.42)
|
3.85 (2.85–5.21)
|
3.97 (2.86–5.50)
|
| |
exp(γ)
|
1.91 (1.38–2.63)
|
2.04 (1.39–3.00)
| |
1.86 (1.35–2.57)
|
|
16
|
exp(β)
|
6.05 (4.35–8.43)
|
3.98 (2.68–5.92)
|
3.88 (2.87–5.25)
|
3.98 (2.88–5.52)
|
| |
exp(γ)
|
2.04 (1.47–2.82)
|
2.11 (1.45–3.07)
| |
1.98 (1.41–2.72)
|
|
17
|
exp(β)
|
5.94 (4.25–8.30)
|
–
|
4.21 (3.09–5.73)
|
3.97 (2.87–5.51)
|
| |
exp(γ)
|
2.06 (1.49–2.84)
|
2.19 (1.48–3.23)
| |
2.02 (1.46–2.79)
|
|
18
|
exp(β)
|
6.14 (4.39–8.59)
|
4.08 (2.18–7.64)
|
4.13 (3.05–5.59)
|
3.99 (2.89–5.51)
|
| |
exp(γ)
|
2.02 (1.47–2.77)
|
2.16 (1.48–3.15)
| |
1.95 (1.43–2.65)
|
|
19
|
exp(β)
|
6.32 (4.52–8.85)
|
4.00 (2.60–6.14)
|
3.94 (2.94–5.29)
|
3.98 (2.87–5.48)
|
| |
exp(γ)
|
2.07 (1.51–2.85)
|
1.98 (1.37–2.88)
| |
2.01 (1.50–2.71)
|
|
20
|
exp(β)
|
6.49 (4.64–9.08)
|
3.94 (2.71–5.74)
|
3.99 (2.98–5.34)
|
3.98 (2.90–5.46)
|
| |
exp(γ)
|
2.16 (1.57–2.98)
|
2.14 (1.47–3.11)
| |
2.05 (1.52–2.76)
|
|
21
|
exp(β)
|
6.35 (4.52–8.91)
|
–
|
4.16 (3.09–5.61)
|
3.96 (2.88–5.46)
|
| |
exp(γ)
|
2.20 (1.60–3.01)
|
2.20 (1.51–3.22)
| |
2.10 (1.53–2.81)
|
- M is the number of control periods and study period = (M + 1) days. 1 period = 1 day for all values of M
- ORSCL: odds ratio by the standard conditional logistic regression; ORVF: odds ratio by the Vines and Farrington’s method; ORMH: odds ratio by the Mantel-Haenszel method; ORG: odds ratio by the Greenland’s method; 95%CI: 95% confidence interval; 2.5–97.5pct: 2.5 to 97.5 percentiles; exp(β): estimate for the exposure variable; exp(γ): estimate for the time-varying confounder
